MEDIROM Healthcare Technologies Inc. Regains Compliance with NASDAQ Continued Listing Requirements

Rhea-AI Summary

MEDIROM Healthcare Technologies (NASDAQ: MRM) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, which received a non-compliance notice on February 27, 2025, was required to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive business days. Nasdaq confirmed that from May 20 to June 3, 2025, MRM's American Depositary Shares consistently met this requirement. The company had been given until August 26, 2025, to resolve the compliance issue, and has now successfully done so ahead of the deadline. With this achievement, Nasdaq has officially closed the matter, confirming MRM's continued listing status.

Positive

• Successfully regained Nasdaq listing compliance ahead of the August 26, 2025 deadline
• Maintained share price above $1.00 for required period, demonstrating price stability
• Avoided potential delisting risk

Negative

• Previously faced delisting risk due to share price falling below $1.00
• Stock price volatility demonstrated by recent need to regain compliance

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NasdaqCM: MRM), a holistic healthcare company based in Japan (“MEDIROM” or the “Company”), today announced that on June 4, 2025, it received a written notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).

On February 27, 2025, the Company received notice from Nasdaq that it was not in compliance with the minimum bid price requirement, which requires listed securities to maintain a minimum closing bid price of $1.00 per share. To regain compliance, the Company’s American Depositary Shares, representing common shares of the Company (“ADSs”), were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The Company was provided 180 calendar days through August 26, 2025, to regain compliance.

On June 4, 2025, Nasdaq confirmed that for the last 10 consecutive business days, from May 20, 2025 to June 3, 2025, the closing bid price of the Company’s ADSs had been $1.00 per share or greater. Accordingly, Nasdaq informed the Company that the Company has regained compliance with Nasdaq Listing rule 5550(a)(2) and that this matter is now closed.

About MEDIROM Healthcare Technologies Inc.
MEDIROM, a holistic healthcare company, operates over 300 wellness salons across Japan, Re.Ra.Ku® being its leading brand, and provides healthcare services. In 2015, MEDIROM entered the health tech business and launched new healthcare programs using an on-demand training app called “Lav®”, which is developed by the Company. MEDIROM also entered the device business in 2020 and has developed a smart tracker, the “MOTHER Bracelet®”. In 2023, MEDIROM launched REMONY, a remote monitoring system for corporate clients, and has received orders from a broad range of industries, including nursing care, transportation, construction, and manufacturing, among others. MEDIROM aims to leverage its diverse portfolio of health-related products and services to collect and manage healthcare data from users and customers, positioning itself as a leader in healthcare big data in Japan. For more information, visit https://medirom.co.jp/en.

Forward-Looking Statements
Certain statements included in this press release relating to MEDIROM are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may include projections and estimates concerning MEDIROM’s possible or assumed future results of operations, financial condition, business strategies and plans, market opportunity, competitive position, industry environment, and potential growth opportunities. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal” or other words that convey the uncertainty of future events or outcomes. You can also identify forward-looking statements by discussions of strategy, plans or intentions. These forward-looking statements include, but are not limited to, forecasts of financial and performance metrics (including key performance indicators), and projections of market size and opportunity. These statements are based on various assumptions and on the current expectations of MEDIROM and its management and are not predictions of actual performance. While MEDIROM’s management considers these assumptions and expectations to be reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond MEDIROM’s control. If the risks materialize or MEDIROM’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. MEDIROM assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Contact
Investor Relations Team
ir@medirom.co.jp

FAQ

What was the minimum share price requirement that MEDIROM (MRM) needed to meet for Nasdaq compliance?

MEDIROM needed to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive business days to meet Nasdaq's listing requirements.

When did MEDIROM (MRM) receive the initial Nasdaq non-compliance notice?

MEDIROM received the initial non-compliance notice from Nasdaq on February 27, 2025.

How long did MEDIROM (MRM) have to regain Nasdaq compliance?

MEDIROM was given 180 calendar days, until August 26, 2025, to regain compliance with Nasdaq's minimum bid price requirement.

What period did MEDIROM (MRM) maintain the required share price to regain compliance?

MEDIROM maintained the required $1.00 minimum share price from May 20, 2025 to June 3, 2025, a period of 10 consecutive business days.

What happens now that MEDIROM (MRM) has regained Nasdaq compliance?

Nasdaq has confirmed that the compliance matter is now closed, and MEDIROM will continue its listing on the Nasdaq Capital Market.